U.S. Cannula Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: U.S. Cannula Market
- ✓Market Size 2024: USD 1.38 billion
- ✓Market Size 2032: USD 2.08 billion
- ✓CAGR: 5.3%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Qualify Compliant Sources Now: Procurement directors and cannula manufacturers should qualify USMCA-compliant and Trade Agreements Act-compliant supply sources by the second quarter of 2026. Section 301 duties and the Commerce Section 232 medical device investigation will reprice China-origin SKUs, and Federal Supply Schedule 65 II A awards favor designated-country production.
Cannula Demand in the United States: Market Overview
The U.S. cannula market was valued at USD 1.38 billion in 2024 and is forecast to reach USD 2.08 billion by 2032. It spans three product families: oxygen nasal cannulas for home and long-term care, high-flow nasal cannulas for hospital respiratory care, and intravascular cannulas for infusion and surgical use. Home oxygen dominates unit volume, while hospitals generate the larger share of revenue because of higher unit prices and sterile single-use requirements.
Government has been the dominant force in shaping demand, primarily through Medicare Part B reimbursement under 42 CFR 414.226 and the Veterans Affairs Federal Supply Schedule 65 II A. Private manufacturers, including Teleflex and Medtronic, lead on device design, safety-engineered catheter features, and hospital group purchasing organization contracts. Policy sets the volume and price floor, and private firms compete for margin above that floor.
Policy-Driven Growth in US Cannula Demand
Medicare Part B oxygen coverage is the largest demand mechanism in the market. Under 42 CFR 414.226, Medicare covers oxygen equipment and supplies, including nasal cannulas, for beneficiaries with qualifying chronic hypoxemia, with the beneficiary paying 20 percent coinsurance after the Part B deductible. Each qualifying patient generates recurring supply orders, so coverage criteria translate directly into monthly cannula volume for durable medical equipment suppliers.
The Hospital Readmissions Reduction Program, created by Section 3025 of the Affordable Care Act, penalizes hospitals with excess 30-day readmissions for chronic obstructive pulmonary disease and heart failure. Hospitals respond by discharging patients on home oxygen with pre-arranged supply, which expands home cannula orders. The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 adds procurement volume through the Strategic National Stockpile administered by the Administration for Strategic Preparedness and Response.
Regulatory Barriers and Compliance Costs
Cannulas are Class II medical devices under the Federal Food, Drug, and Cosmetic Act, requiring premarket notification under Section 510(k) administered by the FDA Center for Devices and Radiological Health. The FDA performance goal is a 90-day review, but total elapsed time including additional information requests frequently exceeds six months. Manufacturers must also register and list devices under 21 CFR Part 807 and pay annual user fees under the Medical Device User Fee Amendments for fiscal years 2023 through 2027.
Reimbursement compliance adds further cost. Medicare durable medical equipment suppliers must meet accreditation, surety bond, and supplier standard requirements under 42 CFR Part 424 Subpart P, administered by the Centers for Medicare and Medicaid Services. The federal Anti-Kickback Statute, 42 U.S.C. 1320a-7b(b), enforced by the HHS Office of Inspector General, restricts free or discounted supplies offered to physicians and patients, requiring formal compliance programs across distribution chains.
Policy-Created Opportunities in the United States
Competitive bidding is reshaping supplier economics. The next round of the Medicare DMEPOS Competitive Bidding Program, finalized in CMS rulemaking in 2024 and scheduled to begin no earlier than 2028, awards contracts by product category. Suppliers with national accreditation, bid capacity, and multi-state fulfillment networks will capture the largest share of contracted Medicare cannula volume.
The Buy American Act and Trade Agreements Act create a protected channel for domestic and designated-country cannulas within federal procurement. The Commerce Department's Section 232 medical device investigation, launched in 2025, positions domestic cannula production for price premiums in federal and Strategic National Stockpile tenders. Manufacturers with U.S. or USMCA-based lines will gain eligibility where competitors sourcing from China face exclusion.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 1.38 billion |
| Market Size 2032 | USD 2.08 billion |
| Growth Rate (CAGR) | 5.3% |
| Most Critical Decision Factor | Medicare and GPO reimbursement eligibility |
| Largest Region | Southeast (Florida, Texas, Georgia) |
| Competitive Structure | Concentrated multinational manufacturing, fragmented DME distribution |
Leading Market Participants
- Teleflex
- Medtronic
- Becton, Dickinson and Company
- Cardinal Health
- Smiths Medical
- ICU Medical
- Vyaire Medical
- Avanos Medical
- Intersurgical
- Salter Labs
Regulatory and Policy Environment
The primary legislation is the Federal Food, Drug, and Cosmetic Act, with device quality requirements set in 21 CFR Part 820. The Quality Management System Regulation takes effect on February 2, 2026, replacing the Quality System Regulation with alignment to ISO 13485:2016. Manufacturers must also comply with medical device reporting under 21 CFR Part 803 and unique device identification under 21 CFR Part 830, with the FDA Center for Devices and Radiological Health responsible for clearance and enforcement, CMS for Medicare coverage, HHS OIG for fraud enforcement, and CBP for Section 301 duty collection.
Compared with regional peers, the U.S. pathway is faster for predicate-based cannulas than the European Union's Medical Device Regulation, Regulation (EU) 2017/745, which requires notified body certification and has transition deadlines extended to 2027 and 2028. Health Canada licensing under SOR/98-282 is administratively heavier for Class II items than 510(k). The upcoming changes that matter most to U.S. manufacturers are the February 2026 quality system transition, the 2028 competitive bidding round, and the outcome of the Section 232 medical device investigation.
Long-Term Policy Outlook for US Cannulas
By 2032, the Quality Management System Regulation will have raised documentation and audit costs across the sector, consolidating share toward large manufacturers such as Medtronic, Teleflex, and BD. The 2028 competitive bidding round will concentrate Medicare supply among accredited national suppliers, compressing margins for small regional durable medical equipment operators. Home oxygen growth will track the Acute Hospital Care at Home waiver authority under Section 1135 of the Social Security Act.
Trade policy will be the decisive variable through 2032. Section 301 duties on China-origin medical consumables will persist, and Section 232 actions will impose additional tariffs on imported devices, rewarding USMCA-based and domestic production. Manufacturers that complete quality system transition and onshore key SKUs before 2028 will hold preferred status in federal procurement and Strategic National Stockpile tenders.
Frequently Asked Questions
Market Segmentation
- Nasal Oxygen Cannulas
- High-Flow Nasal Cannulas
- Peripheral Intravenous Cannulas
- Arterial Cannulas
- Surgical Suction Cannulas
- Hospitals
- Home Healthcare Providers
- Ambulatory Surgical Centers
- Long-Term Care Facilities
- Group Purchasing Organizations
- Durable Medical Equipment Suppliers
- Federal Supply Schedule
- Direct Hospital Sales
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.